While overall rates of sexually transmitted diseases in the U.S. have fallen, the alarming rise in congenital syphilis cases among newborns raises serious health concerns. Experts warn that we must do more to protect vulnerable populations.
In a race against time, Bear River Health officials moved swiftly to protect 11 exposed infants from measles, coordinating a vital response that involved notifying families and administering urgent treatments.
The American College of Obstetricians and Gynecologists has released updated guidance recommending COVID-19, influenza, and RSV vaccinations for pregnant women. These vaccines are shown to protect both mothers and infants from severe respiratory illnesses. Discover why vaccination is essential for a healthy pregnancy.
In a pivotal ruling, a federal judge in New Hampshire granted class-action status to a lawsuit challenging Trump's birthright citizenship order, temporarily blocking its implementation. This decision aims to protect the rights of children born in the U.S. amid ongoing legal battles.
In a groundbreaking move, Novartis has received approval for Coartem® Baby, the first malaria treatment specifically designed for newborns and young infants, addressing a critical healthcare gap in malaria-endemic regions.
Swiss authorities have approved Coartem Baby, the first malaria treatment for newborns under 11 pounds, addressing a significant health gap for vulnerable infants. This sweet cherry-flavored drug can be mixed with breast milk, making it easier to administer.
A new monoclonal antibody called clesrovimab has been recommended for infants to prevent RSV, stirring debate among health experts and advocates. The FDA approved the treatment just weeks ago.
In a pivotal vote, the CDC's advisory committee has recommended the use of clesrovimab, a new monoclonal antibody, for infants under eight months to combat RSV, marking a significant advancement in public health.
Merck's new drug ENFLONSIA has received FDA approval for preventing RSV in newborns and infants, promising significant reductions in hospitalizations and severe respiratory illness. This long-acting monoclonal antibody offers hope for parents facing RSV season challenges.
A groundbreaking CDC study shows a dramatic decline in RSV hospitalizations for infants, with new vaccines and treatments reducing rates by up to 71%. Discover how these advancements are transforming baby care and preventing severe illness.
